Literature DB >> 23785047

Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: influence of tumor origin.

Romain Remark1, Marco Alifano, Isabelle Cremer, Audrey Lupo, Marie-Caroline Dieu-Nosjean, Marc Riquet, Lucile Crozet, Hanane Ouakrim, Jeremy Goc, Aurélie Cazes, Jean-François Fléjou, Laure Gibault, Virginie Verkarre, Jean-François Régnard, Olivier-Nicolas Pagès, Stéphane Oudard, Bernhard Mlecnik, Catherine Sautès-Fridman, Wolf-Herman Fridman, Diane Damotte.   

Abstract

PURPOSE: If immune cells are involved in tumor surveillance and have a prognostic impact in most primary tumors, little is known about their significance in metastases. Because patients' survival is heterogeneous, even at metastatic stages, we hypothesized that immune cells may be involved in the control of metastases. We therefore characterized the tumor immune microenvironment and its prognostic value in colorectal and renal cell carcinoma (RCC) metastases, and compared it to primary tumors. EXPERIMENTAL
DESIGN: We analyzed by immunohistochemistry (n = 192) and qPCR (n = 32) the immune environments of colorectal carcinoma and RCC lung metastases.
RESULTS: Metastases from colorectal carcinoma and RCC have different immune infiltrates. Higher densities of DC-LAMP(+) mature dendritic cells (P < 0.0001) and lower densities of NKp46(+) NK cells (P < 0.0001) were observed in colorectal carcinoma as compared to RCC metastases, whereas densities of T cells were similar. High densities of CD8(+) and DC-LAMP(+) cells correlated with longer overall survival (OS) in colorectal carcinoma (P = 0.008) and shorter OS in RCC (P < 0.0001). High NK-cell densities were associated with improved survival in RCC (P = 0.002) but not in colorectal carcinoma. Densities of immune cells correlated significantly from primary to relapsing metastases for the same patient. A TH1 orientation was found in colorectal carcinoma metastases, whereas a heterogeneous immune gene expression was found in RCC metastases.
CONCLUSIONS: Our results show a major prognostic value of the immune pattern (CD8(+)/DC-LAMP(+) cell densities) in colorectal carcinoma and RCC, reproducible from primary to metastatic tumors, although with opposite clinical impacts, and highlight the role of the tumor cell in shaping its immune environment. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23785047     DOI: 10.1158/1078-0432.CCR-12-3847

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  133 in total

Review 1.  Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.

Authors:  Shona Hendry; Roberto Salgado; Thomas Gevaert; Prudence A Russell; Tom John; Bibhusal Thapa; Michael Christie; Koen van de Vijver; M V Estrada; Paula I Gonzalez-Ericsson; Melinda Sanders; Benjamin Solomon; Cinzia Solinas; Gert G G M Van den Eynden; Yves Allory; Matthias Preusser; Johannes Hainfellner; Giancarlo Pruneri; Andrea Vingiani; Sandra Demaria; Fraser Symmans; Paolo Nuciforo; Laura Comerma; E A Thompson; Sunil Lakhani; Seong-Rim Kim; Stuart Schnitt; Cecile Colpaert; Christos Sotiriou; Stefan J Scherer; Michail Ignatiadis; Sunil Badve; Robert H Pierce; Giuseppe Viale; Nicolas Sirtaine; Frederique Penault-Llorca; Tomohagu Sugie; Susan Fineberg; Soonmyung Paik; Ashok Srinivasan; Andrea Richardson; Yihong Wang; Ewa Chmielik; Jane Brock; Douglas B Johnson; Justin Balko; Stephan Wienert; Veerle Bossuyt; Stefan Michiels; Nils Ternes; Nicole Burchardi; Stephen J Luen; Peter Savas; Frederick Klauschen; Peter H Watson; Brad H Nelson; Carmen Criscitiello; Sandra O'Toole; Denis Larsimont; Roland de Wind; Giuseppe Curigliano; Fabrice André; Magali Lacroix-Triki; Mark van de Vijver; Federico Rojo; Giuseppe Floris; Shahinaz Bedri; Joseph Sparano; David Rimm; Torsten Nielsen; Zuzana Kos; Stephen Hewitt; Baljit Singh; Gelareh Farshid; Sibylle Loibl; Kimberly H Allison; Nadine Tung; Sylvia Adams; Karen Willard-Gallo; Hugo M Horlings; Leena Gandhi; Andre Moreira; Fred Hirsch; Maria V Dieci; Maria Urbanowicz; Iva Brcic; Konstanty Korski; Fabien Gaire; Hartmut Koeppen; Amy Lo; Jennifer Giltnane; Marlon C Rebelatto; Keith E Steele; Jiping Zha; Kenneth Emancipator; Jonathan W Juco; Carsten Denkert; Jorge Reis-Filho; Sherene Loi; Stephen B Fox
Journal:  Adv Anat Pathol       Date:  2017-11       Impact factor: 3.875

Review 2.  The non-small cell lung cancer immune contexture. A major determinant of tumor characteristics and patient outcome.

Authors:  Romain Remark; Christian Becker; Jorge E Gomez; Diane Damotte; Marie-Caroline Dieu-Nosjean; Catherine Sautès-Fridman; Wolf-Herman Fridman; Charles A Powell; Nasser K Altorki; Miriam Merad; Sacha Gnjatic
Journal:  Am J Respir Crit Care Med       Date:  2015-02-15       Impact factor: 21.405

Review 3.  Immune Cell Infiltration and Tertiary Lymphoid Structures as Determinants of Antitumor Immunity.

Authors:  Victor H Engelhard; Anthony B Rodriguez; Ileana S Mauldin; Amber N Woods; J David Peske; Craig L Slingluff
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

4.  A Strong B-cell Response Is Part of the Immune Landscape in Human High-Grade Serous Ovarian Metastases.

Authors:  Anne Montfort; Oliver Pearce; Eleni Maniati; Benjamin G Vincent; Lisa Bixby; Steffen Böhm; Thomas Dowe; Edmund H Wilkes; Probir Chakravarty; Richard Thompson; Joanne Topping; Pedro R Cutillas; Michelle Lockley; Jonathan S Serody; Melania Capasso; Frances R Balkwill
Journal:  Clin Cancer Res       Date:  2016-06-27       Impact factor: 12.531

5.  Tumor infiltrating B-cells signal functional humoral immune responses in breast cancer.

Authors:  Soizic Garaud; Laurence Buisseret; Cinzia Solinas; Chunyan Gu-Trantien; Alexandre de Wind; Gert Van den Eynden; Celine Naveaux; Jean-Nicolas Lodewyckx; Anaïs Boisson; Hughes Duvillier; Ligia Craciun; Lieveke Ameye; Isabelle Veys; Marianne Paesmans; Denis Larsimont; Martine Piccart-Gebhart; Karen Willard-Gallo
Journal:  JCI Insight       Date:  2019-08-13

6.  NKp30 isoforms and NKp46 transcripts in metastatic melanoma patients: Unique NKp30 pattern in rare melanoma patients with favorable evolution.

Authors:  Meriem Messaoudene; Giulia Fregni; David Enot; Nicolas Jacquelot; Emmanuelle Neves; Nathalie Germaud; Henri Jean Garchon; Wahid Boukouaci; Ryad Tamouza; Johan Chanal; Marie-Françoise Avril; Antoine Toubert; Laurence Zitvogel; Sylvie Rusakiewicz; Anne Caignard
Journal:  Oncoimmunology       Date:  2016-03-10       Impact factor: 8.110

7.  NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients.

Authors:  Sylvie Rusakiewicz; Aurélie Perier; Michaela Semeraro; Jonathan M Pitt; Elke Pogge von Strandmann; Katrin S Reiners; Sandrine Aspeslagh; Christelle Pipéroglou; Frédéric Vély; Alexandre Ivagnes; Sarah Jegou; Niels Halama; Loic Chaigneau; Pierre Validire; Christos Christidis; Thierry Perniceni; Bruno Landi; Anne Berger; Nicolas Isambert; Julien Domont; Sylvie Bonvalot; Philippe Terrier; Julien Adam; Jean-Michel Coindre; Jean-François Emile; Vichnou Poirier-Colame; Kariman Chaba; Benedita Rocha; Anne Caignard; Antoine Toubert; David Enot; Joachim Koch; Aurélien Marabelle; Marion Lambert; Sophie Caillat-Zucman; Serge Leyvraz; Christian Auclair; Eric Vivier; Alexander Eggermont; Christophe Borg; Jean-Yves Blay; Axel Le Cesne; Olivier Mir; Laurence Zitvogel
Journal:  Oncoimmunology       Date:  2016-04-25       Impact factor: 8.110

8.  Impact of cyclooxygenase-2 and prostaglandin-E2 expression on clinical outcome after pulmonary metastasectomy.

Authors:  Christian Lang; Emilie Hrdliczka; Thomas Schweiger; Olaf Glueck; Gerrit Lewik; Stefan Schwarz; Alberto Benazzo; György Lang; Walter Klepetko; Konrad Hoetzenecker
Journal:  J Thorac Dis       Date:  2017-03       Impact factor: 2.895

Review 9.  Trial Watch: Therapeutic vaccines in metastatic renal cell carcinoma.

Authors:  Pierre Combe; Eleonore de Guillebon; Constance Thibault; Clémence Granier; Eric Tartour; Stéphane Oudard
Journal:  Oncoimmunology       Date:  2015-03-19       Impact factor: 8.110

10.  Accumulation of tolerogenic human 6-sulfo LacNAc dendritic cells in renal cell carcinoma is associated with poor prognosis.

Authors:  Marieta Toma; Rebekka Wehner; Anja Kloß; Linda Hübner; Georgia Fodelianaki; Kati Erdmann; Susanne Füssel; Stefan Zastrow; Matthias Meinhardt; Barbara Seliger; Dorothee Brech; Elfriede Noessner; Torsten Tonn; Knut Schäkel; Martin Bornhäuser; Michael P Bachmann; Manfred P Wirth; Gustavo Baretton; Marc Schmitz
Journal:  Oncoimmunology       Date:  2015-03-02       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.